The capsule of Cryptococcus neoformans

References

• McClelland EE, Bernhardt P, Casadevall A. Estimating the relative contribution s of virulence factors for pathogenic microbes. Infect Immun. 2006;74:1500–4. doi:10.1128/IAI.74.3.1500-1504.2006
   PubMed Web of Science ®Google Scholar
• Chang YC, Kwon-Chung KJ. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol. 1994;14:4912–9. doi:10.1128/MCB.14.7.4912
   PubMed Web of Science ®Google Scholar
• Chang YC, Penoyer LA, Kwon-Chung KJ. The second capsule gene of cryptococcus neoformans, CAP64, is essential for virulence. Infect Immun. 1996;64:1977–83.
   PubMed Web of Science ®Google Scholar
• Kabanda T, Siedner MJ, Klausner JD, et al. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014;58:113–6. doi:10.1093/cid/cit641
   PubMed Web of Science ®Google Scholar
• O'Meara TR, Alspaugh JA. The Cryptococcus neoformans capsule: a sword and a shield. Clin Microbiol Rev. 2012;25:387–408. doi:10.1128/CMR.00001-12
   PubMed Web of Science ®Google Scholar
• Haynes BC, Skowyra ML, Spencer SJ, et al. Toward an integrated model of capsule regulation in Cryptococcus neoformans. PLoS Pathog. 2011;7:e1002411. doi:10.1371/journal.ppat.1002411
   PubMed Web of Science ®Google Scholar
• Vecchiarelli A, Pericolini E, Gabrielli E, et al. Elucidating the immunological function of the Cryptococcus neoformans capsule. Future microbiology. 2013;8:1107–16. doi:10.2217/fmb.13.84
   PubMed Web of Science ®Google Scholar
• Garcia-Rodas R, Zaragoza O. Catch me if you can: phagocytosis and killing avoidance by Cryptococcus neoformans. FEMS immunology and medical microbiology. 2012;64:147–61. doi:10.1111/j.1574-695X.2011.00871.x
   PubMed Web of Science ®Google Scholar
• Kumar P, Yang M, Haynes BC, et al. Emerging themes in cryptococcal capsule synthesis. Curr Opin Struct Biol. 2011;21:597–602. doi:10.1016/j.sbi.2011.08.006
   PubMed Web of Science ®Google Scholar
• Klutts JS, Yoneda A, Reilly MC, et al. Glycosyltransferases and their products: cryptococcal variations on fungal themes. FEMS Yeast Res. 2006;6:499–512. doi:10.1111/j.1567-1364.2006.00054.x
   PubMed Web of Science ®Google Scholar
• Doering TL. How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans. Annu Rev Microbiol. 2009;63:223–47. doi:10.1146/annurev.micro.62.081307.162753
   PubMed Web of Science ®Google Scholar
• Ding H, Mayer FL, Sanchez-Leon E, et al. Networks of fibers and factors: regulation of capsule formation in Cryptococcus neoformans. F1000Res. 2016;5. pii: F1000 Faculty Rev-1786. doi:10.12688/f1000research.8854.1
   Google Scholar
• Maxson ME, Cook E, Casadevall A, et al. The volume and hydration of the Cryptococcus neoformans polysaccharide capsule. Fungal Genet Biol. 2007;44:180–6. doi:10.1016/j.fgb.2006.07.010
   PubMed Web of Science ®Google Scholar
• Cleare W, Casadevall A. Scanning electron microscopy of encapsulated and non-encapsulated Cryptococcus neoformans and the effect of glucose on capsular polysaccharide release. Med Mycol. 1999;37:235–43.
   PubMed Web of Science ®Google Scholar
• Araujo GR, Fontes GN, Leao D, et al. Cryptococcus neoformans capsular polysaccharides form branched and complex filamentous networks viewed by high-resolution microscopy. Journal of structural biology. 2016;193:75–82. doi:10.1016/j.jsb.2015.11.010
   PubMed Web of Science ®Google Scholar
• Maxson ME, Dadachova E, Casadevall A, et al. Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule. Eukaryot Cell. 2007;6:95–109. doi:10.1128/EC.00306-06
   PubMedGoogle Scholar
• Gates MA, Thorkildson P, Kozel TR. Molecular architecture of the Cryptococcus neoformans capsule. Mol Microbiol. 2004;52:13–24. doi:10.1111/j.1365-2958.2003.03957.x
   PubMed Web of Science ®Google Scholar
• Bryan RA, Zaragoza O, Zhang T, et al. Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryot Cell. 2005;4:465–75. doi:10.1128/EC.4.2.465-475.2005
   PubMedGoogle Scholar
• Zaragoza O, McClellan EE, Telzak A, et al. Equatorial ring-ling like channels in the Cryptococcus neoformans polysaccharide capsule. FEMS Yeast Res. 2006;6:662–6. doi:10.1111/j.1567-1364.2006.00070.x
   PubMed Web of Science ®Google Scholar
• Frases S, Nimrichter L, Viana NB, et al. Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell. 2008;7:319–27. doi:10.1128/EC.00378-07
   PubMed Web of Science ®Google Scholar
• McFadden DC, De Jesus M, Casadevall A. The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J Biol Chem. 2005;281:1868–75. doi:10.1074/jbc.M509465200
   PubMed Web of Science ®Google Scholar
• Frases S, Pontes B, Nimrichter L, et al. Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules. Proc Natl Acad Sci U S A. 2009;106:1228–33. doi:10.1073/pnas.0808995106
   PubMed Web of Science ®Google Scholar
• Cordero RJ, Frases S, Guimaraes AJ, et al. Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. Mol Microbiol. 2011;79:1101–17. doi:10.1111/j.1365-2958.2010.07511.x
   PubMed Web of Science ®Google Scholar
• Cordero RJ, Pontes B, Guimaraes AJ, et al. Chronological aging is associated with biophysical and chemical changes in the capsule of Cryptococcus neoformans. Infect Immun. 2011;79:4990–5000. doi:10.1128/IAI.05789-11
   PubMed Web of Science ®Google Scholar
• Frases S, Viana NB, Casadevall A. Biophysical methods for the study of microbial surfaces. Front Microbiol. 2011;2:207. doi:10.3389/fmicb.2011.00207
   PubMed Web of Science ®Google Scholar
• Pontes B, Frases S. The Cryptococcus neoformans capsule: lessons from the use of optical tweezers and other biophysical tools. Front Microbiol. 2015;6:640. doi:10.3389/fmicb.2015.00640
   PubMed Web of Science ®Google Scholar
• Frases S, Pontes B, Nimrichter L, et al. The elastic properties of the Cryptococcus neoformans capsule. Biophys J. 2009;97:937–45. doi:10.1016/j.bpj.2009.04.043
   PubMed Web of Science ®Google Scholar
• Cordero RJ, Pontes B, Frases S, et al. Antibody binding to Cryptococcus neoformans impairs budding by altering capsular mechanical properties. J Immunol. 2013;190:317–23. doi:10.4049/jimmunol.1202324
   PubMed Web of Science ®Google Scholar
• Guazzelli L, McCabe O, Oscarson S. Synthesis of part structures of Cryptococcus neoformans serotype C capsular polysaccharide. Carbohydrate research. 2016;433:5–13. doi:10.1016/j.carres.2016.06.012
   PubMed Web of Science ®Google Scholar
• Oscarson S, Alpe M, Svahnberg P, et al. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures. Vaccine. 2005;23:3961–72. doi:10.1016/j.vaccine.2005.02.029
   PubMed Web of Science ®Google Scholar
• Merrifield EH, Stephen aM. Structural investigations of two capsular polysaccharides from Cryptococcus neoformans. Carb Res. 1980;86:69–76. doi:10.1016/S0008-6215(00)84582-6
   Web of Science ®Google Scholar
• Cherniak R, Reiss E, Slodki ME, et al. Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A. Mol Immunol. 1980;17:1025–32. doi:10.1016/0161-5890(80)90096-6
   PubMed Web of Science ®Google Scholar
• Belay T, Cherniak R, Kozel TR, et al. Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. Infect Immun. 1997;65:718–28.
   PubMed Web of Science ®Google Scholar
• Kozel TR, Levitz SM, Dromer F, et al. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains. Infect Immun. 2003;71:2868–75. doi:10.1128/IAI.71.5.2868-2875.2003
   PubMed Web of Science ®Google Scholar
• Cherniak R, Valafar H, Morris LC, et al. Cryptococcus neoformans chemotyping by quantitative analysis of 1H NMR spectra of glucuronoxylomannans using a computer simulated artificial neural network. Clin Diagn Lab Immunol. 1998;5:146–59.
   PubMedGoogle Scholar
• Nimrichter L, Frases S, Cinelli LP, et al. Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell. 2007;6:1400–10. doi:10.1128/EC.00122-07
   PubMedGoogle Scholar
• McFadden DC, Fries BC, Wang F, et al. Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans. Eukaryot Cell. 2007;6:1464–73. doi:10.1128/EC.00162-07
   PubMed Web of Science ®Google Scholar
• Park YD, Shin S, Panepinto J, et al. A role for LHC1 in higher order structure and complement binding of the Cryptococcus neoformans capsule. PLoS Pathog. 2014;10:e1004037. doi:10.1371/journal.ppat.1004037
   PubMed Web of Science ®Google Scholar
• Levitz SM, Specht CA. The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins. FEMS Yeast Res. 2006;6:513–24. doi:10.1111/j.1567-1364.2006.00071.x
   PubMed Web of Science ®Google Scholar
• Madu UL, Ogundeji AO, Mochochoko BM, et al. Cryptococcal 3-Hydroxy Fatty Acids Protect Cells Against Amoebal Phagocytosis. Front Microbiol. 2015;6:1351. doi:10.3389/fmicb.2015.01351
   PubMed Web of Science ®Google Scholar
• Nicola AM, Frases S, Casadevall A. Lipophilic dye staining of Cryptococcus neoformans extracellular vesicles and capsule. Eukaryot Cell. 2009;8:1373–80. doi:10.1128/EC.00044-09
   PubMed Web of Science ®Google Scholar
• Heiss C, Klutts JS, Wang Z, et al. The structure of Cryptococcus neoformans galactoxylomannan contains beta-D-glucuronic acid. Carbohydrate Research. 2009;344:915–20. doi:10.1016/j.carres.2009.03.003
   PubMed Web of Science ®Google Scholar
• Jesus MD, Nicola AM, Chow SK, et al. Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans. Virulence. 2010;1:500–8. doi:10.4161/viru.1.6.13451
   PubMed Web of Science ®Google Scholar
• Vaishnav VV, Bacon BE, O'Neill M, et al. Structural characterization of the galactoxylomannan of Cryptococcus neoformans Cap67. Carbohydrate research. 1998;306:315–30. doi:10.1016/S0008-6215(97)10058-1
   PubMed Web of Science ®Google Scholar
• Previato JO, Vinogradov E, Maes E, et al. Distribution of the O-acetyl groups and beta-galactofuranose units in galactoxylomannans of the opportunistic fungus Cryptococcus neoformans. Glycobiology. 2017;27:582–92.
   PubMed Web of Science ®Google Scholar
• Azurmendi HF, Battistel MD, Zarb J, et al. The beta-reducing end in alpha(2-8)-polysialic acid constitutes a unique structural motif. Glycobiology. 2017;27:900–11. doi:10.1093/glycob/cwx025
   PubMed Web of Science ®Google Scholar
• Battistel MD, Shangold M, Trinh L, et al. Evidence for helical structure in a tetramer of alpha2-8 sialic acid: unveiling a structural antigen. J Am Chem Soc. 2012;134:10717–20. doi:10.1021/ja300624j
   PubMed Web of Science ®Google Scholar
• Zaragoza O, Casadevall A. Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online. 2004;6:10–5. doi:10.1251/bpo68
   PubMedGoogle Scholar
• Zaragoza O, Telzak A, Bryan RA, et al. The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol. 2006;59:67–83. doi:10.1111/j.1365-2958.2005.04928.x
   PubMed Web of Science ®Google Scholar
• Garcia-Rodas R, Cordero RJ, Trevijano-Contador N, et al. Capsule Growth in Cryptococcus neoformans Is Coordinated with Cell Cycle Progression. MBio. 2014;5:e00945–14. doi:10.1128/mBio.00945-14.
   PubMed Web of Science ®Google Scholar
• Feldmesser M, Kress Y, Casadevall A. Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology. 2001;147:2355–65. doi:10.1099/00221287-147-8-2355
   PubMed Web of Science ®Google Scholar
• Cordero RJ, Bergman A, Casadevall A. Temporal behavior of capsule enlargement by Cryptococcus neoformans. Eukaryotic Cell. 2013;12:1383–8. doi:10.1128/EC.00163-13
   PubMedGoogle Scholar
• Charlier C, Chretien F, Baudrimont M, et al. Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol. 2005;166:421–32. doi:10.1016/S0002-9440(10)62265-1
   PubMed Web of Science ®Google Scholar
• Vartivarian SE, Anaissie EJ, Cowart RE, et al. Regulation of cryptococcal capsular polysaccharide by iron. J Infect Dis. 1993;167:186–90. doi:10.1093/infdis/167.1.186
   PubMed Web of Science ®Google Scholar
• Granger DL, Perfect JR, Durack DT. Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest. 1985;76:508–16.
   PubMed Web of Science ®Google Scholar
• Guimaraes AJ, Frases S, Cordero RJ, et al. Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo. Cell Microbiol. 2010;12:740–53. doi:10.1111/j.1462-5822.2010.01430.x
   PubMed Web of Science ®Google Scholar
• Dystra MA, Friedman L, Murphy JW. Capsule size of Cryptococcus neoformans: control and relationship to virulence. Infect Immun. 1977;16:129–35.
   PubMed Web of Science ®Google Scholar
• Feldmesser M, Rivera J, Kress Y, et al. Antibody interactions with the capsule of Cryptococcus neoformans. Infect Immun. 2000;68:3642–50. doi:10.1128/IAI.68.6.3642-3650.2000
   PubMed Web of Science ®Google Scholar
• Ophir T, Gutnick DL. A role for exopolysaccharides in the protection of microorganisms from desiccation. Appl Environ Microbiol. 1994;60:740–5.
   PubMed Web of Science ®Google Scholar
• Zaragoza O, Chrisman CJ, Castelli MV, et al. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol. 2008;10:2043–57. doi:10.1111/j.1462-5822.2008.01186.x
   PubMed Web of Science ®Google Scholar
• Steenbergen JN, Shuman HA, Casadevall A. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci. 2001;18:15245–50. doi:10.1073/pnas.261418798
   Google Scholar
• Chrisman CJ, Albuquerque P, Guimaraes AJ, et al. Phospholipids trigger Cryptococcus neoformans capsule enlargement during interactions with amoebae and macrophages. Plos Pathogens. 2011;7:e1002047. doi:10.1371/journal.ppat.1002047
   PubMed Web of Science ®Google Scholar
• Macura N, Zhang T, Casadevall A. The dependence of macrophage phagocytic efficacy on antibody concentration. Infect Immun. 2007;75:1904–15. doi:10.1128/IAI.01258-06.
   PubMed Web of Science ®Google Scholar
• Zaragoza O, Casadevall A. Antibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of non-protective antibodies. Infect Immun. 2004;72:4271–4. doi:10.1128/IAI.72.7.4271-4274.2004
   PubMed Web of Science ®Google Scholar
• Macher AM, Bennett JE, Gadek JE, et al. Complement depletion in cryptococcal sepsis. J Immunol. 1978;120:1686–90.
   PubMed Web of Science ®Google Scholar
• Rohatgi S, Pirofski LA. Host immunity to Cryptococcus neoformans. Future microbiology. 2015;10:565–81. doi:10.2217/fmb.14.132
   PubMed Web of Science ®Google Scholar
• Zaragoza O, Taborda CP, Casadevall A. The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol. 2003;33:1957–67. doi:10.1002/eji.200323848
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Lee SC, Casadevall A. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun. 1995;63:573–9.
   PubMed Web of Science ®Google Scholar
• Casadevall A, Perfect JR. Cryptococcus neoformans. Washington, DC: American Society for Microbiology; 1998
   Google Scholar
• Cherniak R, Morris LC, Belay T, et al. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect Immun. 1995;63:1899–905.
   PubMed Web of Science ®Google Scholar
• Chen Y, Farrer RA, Giamberardino C, et al. Microevolution of Serial Clinical Isolates of Cryptococcus neoformans var. grubii and C gattii MBio. 2017;8.
   Google Scholar
• Bouklas T, Fries BC. Aging: an emergent phenotypic trait that contributes to the virulence of Cryptococcus neoformans. Future microbiology. 2015;10:191–7. doi:10.2217/fmb.14.124
   PubMed Web of Science ®Google Scholar
• Vecchiarelli A, Pericolini E, Gabrielli E, et al. Cryptococcus neoformans galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy. Immunotherapy. 2011;3:997–1005. doi:10.2217/imt.11.86
   PubMed Web of Science ®Google Scholar
• Albuquerque PC, Fonseca FL, Dutra FF, et al. Cryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct. Future microbiology. 2014;9:147–61. doi:10.2217/fmb.13.163
   PubMed Web of Science ®Google Scholar
• Monari C, Bevilacqua S, Piccioni M, et al. A microbial polysaccharide reduces the severity of rheumatoid arthritis by influencing Th17 differentiation and proinflammatory cytokines production. Journal of immunology (Baltimore, Md : 1950). 2009;183:191–200. doi:10.4049/jimmunol.0804144
   PubMed Web of Science ®Google Scholar
• Piccioni M, Monari C, Kenno S, et al. A purified capsular polysaccharide markedly inhibits inflammatory response during endotoxic shock. Infect Immun. 2013;81:90–8. doi:10.1128/IAI.00553-12
   PubMed Web of Science ®Google Scholar
• Shoham S, Huang C, Chen JM, et al. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol. 2001;166:4620–6. doi:10.4049/jimmunol.166.7.4620
   PubMed Web of Science ®Google Scholar
• Lipovsky MM, Gekker G, Anderson WR, et al. Phagocytosis of nonopsonized Cryptococcus neoformans by swine microglia involves CD14 receptors. Clinical immunology and immunopathology. 1997;84:208–11. doi:10.1006/clin.1997.4381
   PubMedGoogle Scholar
• Robertson EJ, Najjuka G, Rolfes MA, et al. Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. The Journal of infectious diseases. 2014;209:74–82. doi:10.1093/infdis/jit435
   PubMed Web of Science ®Google Scholar
• Bojarczuk A, Miller KA, Hotham R, et al. Cryptococcus neoformans Intracellular Proliferation and Capsule Size Determines Early Macrophage Control of Infection. Scientific reports. 2016;6:21489. doi:10.1038/srep21489
   PubMed Web of Science ®Google Scholar
• Sabiiti W, Robertson E, Beale MA, et al. Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. J Clin Invest. 2014;124:2000–8. doi:10.1172/JCI72950
   PubMed Web of Science ®Google Scholar
• Urai M, Kaneko Y, Ueno K, et al. Evasion of Innate Immune Responses by the Highly Virulent Cryptococcus gattii by Altering Capsule Glucuronoxylomannan Structure. Frontiers in cellular and infection microbiology. 2015;5:101.
   PubMed Web of Science ®Google Scholar
• Pool A, Lowder L, Wu Y, et al. Neurovirulence of Cryptococcus neoformans determined by time course of capsule accumulation and total volume of capsule in the brain. J Neurovirol. 2013;19:228–38. doi:10.1007/s13365-013-0169-7
   PubMed Web of Science ®Google Scholar
• Rivera J, Feldmesser M, Cammer M, et al. Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect Immun. 1998;66:5027–30.
   PubMed Web of Science ®Google Scholar
• Bowen A, Wear MP, Cordero RJ, et al. A Monoclonal Antibody to Cryptococcus neoformans Glucuronoxylomannan Manifests Hydrolytic Activity for Both Peptides and Polysaccharides. The Journal of biological chemistry. 2017;292:417–34. doi:10.1074/jbc.M116.767582
   PubMed Web of Science ®Google Scholar
• Trevijano-Contador N, Rossi SA, Alves E, et al. Capsule Enlargement in Cryptococcus neoformans Is Dependent on Mitochondrial Activity. Front Microbiol. 2017;8:1423. doi:10.3389/fmicb.2017.01423
   PubMed Web of Science ®Google Scholar
• Nguyen LN, Lopes LC, Cordero RJ, et al. Sodium butyrate inhibits pathogenic yeast growth and enhances the functions of macrophages. The Journal of antimicrobial chemotherapy. 2011;66:2573–80. doi:10.1093/jac/dkr358
   PubMed Web of Science ®Google Scholar
• Zaragoza O, Mihu C, Casadevall A, et al. Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection. Antimicrob Agents Chemother. 2005;49:4358–61. doi:10.1128/AAC.49.10.4358-4361.2005
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kwon-Chung KJ, Milne GWA, et al. Relationship between polyene resistance and sterol compositions in Cryptococcus neoformans. Antimicrob Agents Chemotherap. 1975;7:99–106. doi:10.1128/AAC.7.1.99
   PubMed Web of Science ®Google Scholar
• Santana AG, Tysoe C, Hu G, et al. Fungal Glycolipid Hydrolase Inhibitors and Their Effect on Cryptococcus neoformans. Chembiochem. 2017;18:284–90. doi:10.1002/cbic.201600538
   PubMed Web of Science ®Google Scholar
• Vitale RG, Pascuccelli V, Afeltra J. Influence of capsule size on the in vitro activity of antifungal agents against clinical Cryptococcus neoformans var. grubii strains Journal of medical microbiology. 2012;61:384–8. doi:10.1099/jmm.0.036152-0
   PubMed Web of Science ®Google Scholar
• Yoneda A, Doering TL. Regulation of Cryptococcus neoformans capsule size is mediated at the polymer level. Eukaryotic cell. 2008;7:546–9. doi:10.1128/EC.00437-07
   PubMedGoogle Scholar
• Yoneda A, Doering TL. A eukaryotic capsular polysaccharide is synthesized intracellularly and secreted via exocytosis. Mol Biol Cell. 2006;17:5131–40. doi:10.1091/mbc.E06-08-0701
   PubMed Web of Science ®Google Scholar
• Rodrigues ML, Nimrichter L, Oliveira DL, et al. Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot Cell. 2007;6:48–59. doi:10.1128/EC.00318-06
   PubMed Web of Science ®Google Scholar
• Godinho RM, Crestani J, Kmetzsch L, et al. The vacuolar-sorting protein Snf7 is required for export of virulence determinants in members of the Cryptococcus neoformans complex. Sci Rep. 2014;4:6198. doi:10.1038/srep06198
   PubMed Web of Science ®Google Scholar
• Rizzo J, Oliveira DL, Joffe LS, et al. Role of the Apt1 protein in polysaccharide secretion by Cryptococcus neoformans. Eukaryotic cell. 2014;13:715–26. doi:10.1128/EC.00273-13
   PubMedGoogle Scholar
• Kmetzsch L, Joffe LS, Staats CC, et al. Role for Golgi reassembly and stacking protein (GRASP) in polysaccharide secretion and fungal virulence. Mol Microbiol. 2011;81:206–18. doi:10.1111/j.1365-2958.2011.07686.x
   PubMed Web of Science ®Google Scholar
• Sebolai OM, Pohl CH, Botes PJ, et al. 3-hydroxy fatty acids found in capsules of Cryptococcus neoformans. Canadian journal of microbiology. 2007;53:809–12. doi:10.1139/W07-045
   PubMed Web of Science ®Google Scholar
• Oliveira DL, Nakayasu ES, Joffe LS, et al. Biogenesis of extracellular vesicles in yeast: Many questions with few answers. Commun Integr Biol. 2010;3:533–5. doi:10.4161/cib.3.6.12756
   PubMedGoogle Scholar
• Reese AJ, Doering TL. Cell wall alpha-1,3-glucan is required to anchor the Cryptococcus neoformans capsule. Molecular microbiology. 2003;50:1401–9. doi:10.1046/j.1365-2958.2003.03780.x
   PubMed Web of Science ®Google Scholar
• Ramos CL, Fonseca FL, Rodrigues J, et al. Chitin-like molecules associate with Cryptococcus neoformans glucuronoxylomannan to form a glycan complex with previously unknown properties. Eukaryot Cell. 2012;11:1086–94. doi:10.1128/EC.00001-12
   PubMedGoogle Scholar